← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

Shenouda Maged

Chief Financial Officer | Officer

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001658369

Purchase history

Companies traded
1
Purchases · 12M
3
Purchases · 24M
4
Average purchase
$522.3K
Median purchase
$470.6K
Gross purchase value
$2.1M

Companies: RELMADA THERAPEUTICS, INC.

4 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-09-11RELMADA THERAPEUTICS, INC.RLMDChief Financial Officer | Officer$844.0KOpen filing
2025-12-16RELMADA THERAPEUTICS, INC.RLMDChief Financial Officer | Officer$48.1KOpen filing
2025-11-06RELMADA THERAPEUTICS, INC.RLMDChief Financial Officer | Officer$1.1MOpen filing
2025-05-20RELMADA THERAPEUTICS, INC.RLMDChief Financial Officer | Officer$97.3KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

No completed point-in-time price outcome is available yet.

Research patterns

First purchase in 12M
0/3
Large purchase ≥ $100k
2/4
Cluster buying · 15D
4/4
Buying the dip
0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.